- Home
- KPRX vs PMCB Comparison
KPRX vs PMCB Comparison
Compare KPRX & PMCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPRX
- PMCB
- Stock Information
- Founded
- KPRX 1998
- PMCB 1996
- Country
- KPRX United States
- PMCB United States
- Employees
- KPRX N/A
- PMCB N/A
- Industry
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- PMCB Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- KPRX Health Care
- PMCB Health Care
- Exchange
- KPRX Nasdaq
- PMCB Nasdaq
- Market Cap
- KPRX 12.0M
- PMCB 11.4M
- IPO Year
- KPRX N/A
- PMCB N/A
- Fundamental
- Price
- KPRX $3.47
- PMCB $1.76
- Analyst Decision
- KPRX Strong Buy
- PMCB
- Analyst Count
- KPRX 1
- PMCB 0
- Target Price
- KPRX $10.00
- PMCB N/A
- AVG Volume (30 Days)
- KPRX 46.3K
- PMCB 27.2K
- Earning Date
- KPRX 03-24-2025
- PMCB 03-17-2025
- Dividend Yield
- KPRX N/A
- PMCB N/A
- EPS Growth
- KPRX N/A
- PMCB N/A
- EPS
- KPRX 1.69
- PMCB 0.74
- Revenue
- KPRX $16,020,000.00
- PMCB N/A
- Revenue This Year
- KPRX N/A
- PMCB N/A
- Revenue Next Year
- KPRX N/A
- PMCB N/A
- P/E Ratio
- KPRX $2.05
- PMCB $2.37
- Revenue Growth
- KPRX N/A
- PMCB N/A
- 52 Week Low
- KPRX $3.00
- PMCB $1.39
- 52 Week High
- KPRX $6.75
- PMCB $2.58
- Technical
- Relative Strength Index (RSI)
- KPRX 44.69
- PMCB 60.08
- Support Level
- KPRX $3.40
- PMCB $1.57
- Resistance Level
- KPRX $3.75
- PMCB $1.66
- Average True Range (ATR)
- KPRX 0.22
- PMCB 0.12
- MACD
- KPRX -0.03
- PMCB 0.02
- Stochastic Oscillator
- KPRX 37.65
- PMCB 68.89
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
About PMCB PharmaCyte Biotech Inc.
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.